InVivo Anti-Human PRLR Monoclonal Antibody (TBS10367)
$489.00 – $2,399.00
Target: PRLR, PRL-R, Prolactin receptor.
| SKU | Stock | SIZE (mg) | Price | Quantity | ||
|---|---|---|---|---|---|---|
| TBS10367-0.5MG | Yes | 0.5 MG | $489.00 | |||
| TBS10367-1MG | Yes | 1 MG | $719.00 | |||
| TBS10367-5MG | Yes | 5 MG | $2,399.00 |
- Description
- Terms
- Additional information
- Documents
- Reviews (0)
Description
Description
Tribioscience in vivo Anti-Human PRLR Antibody is a monoclonal antibody targeting the human prolactin receptor (PRLR), which regulates breast development, milk secretion, ovarian function, and reproductive processes. It is used in research on breast cancer, infertility, and immune regulation. By blocking prolactin-PRLR interaction, it can inhibit tumor cell growth, offering potential for targeted cancer therapies.
Synonyms
InVivoMAb Anti-Human PRLR Antibody, PRLR Antibody, Anti-Human PRLR Antibody.
Product Details
| Applications: | ELISA, Neutralization |
| Species reactivity: | Human |
| Host: | Human |
| Isotype: | IgG2, lambda |
| Target: | PRLR, PRL-R, Prolactin receptor. |
| Uniprot: | P16471 |
| Concentration: | 3 mg/ml |
| Purity: | >95% |
| Formulation: | Liquid |
| Storage buffer: | 0.01M PBS, pH 7.4. |
| Purification: | Protein A/G purified from cell culture supernatant. |
| Clonality: | Monoclonal |
| Storage: | Store -20°C up to 12 months, and -80°C for long term. Avoid repeated freeze-thaw cycles. |
Data Image
Fig. 1. SDS-PAGE for InVivoMAb Anti-Human PRLR Antibody
MW: Molecular Weight (kDa) Marker.
R: Reducing conditions.
NR: Non-Reducing conditions.
Fig. 2. Detects recombinant Prolactin receptor in indirect ELISA.
Research use only.
Additional information
| SIZE (mg) | 1 MG, 5 MG, 0.5 MG |
|---|
Datasheet:
TBS10367 InVivoMAb Anti-Human PRLR Antibody_Datasheet
MSDS:
TBS10367 InVivoMAb Anti-Human PRLR Antibody_MSDS
Research use only.
Be the first to review “InVivo Anti-Human PRLR Monoclonal Antibody (TBS10367)”
You must be logged in to post a review.
Reviews
There are no reviews yet.